We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis.
- Authors
Zinzani, P. L.; Feldman, T.; Collins, G.; Zain, J.; Khot, A.; Kim, J. S.; Morschhauser, F.; Kim, T. M.; Roderick, J.; Yoon, J. L.; Sharma, S.; Saeh, J.; Dai, J.; Reyes, R.; Olsson, R. F.; Shortt, J.
- Abstract
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T-cell Lymphoma (PTCL): Early trial analysis B Conclusions: b Preliminary results show encouraging clinical activity with AZD4573 monotherapy in pts with r/r PTCL, including 3 CRs and one CMR after initial PD. B Introduction: b Pts with r/r PTCL have limited treatment options and poor outcomes to standard of care therapy.
- Subjects
T-cell lymphoma; SEPTIC shock; ALKYLATING agents; RNA polymerases; STOCK ownership
- Publication
Hematological Oncology, 2023, Vol 41, p568
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_425